|
Press Releases |
|
|
|
Friday, October 21, 2016 |
|
Nanobiotix's Partner, PharmaEngine, Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia |
NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October. more info >> |
|
Tuesday, October 4, 2016 |
|
Nanobiotix Strengthens U.S. Leadership with Appointments of Head of U.S. Clinical Development and Director of Investor Relations |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has strengthened its U.S. leadership team with the appointments of Dr. Mihail Obrocea as the Head of U.S. Clinical Development and Noel Kurdi as the Director of Investor Relations. more info >> |
|
Tuesday, September 20, 2016 |
|
Bpifrance Grants Nanobiotix a 2M EUR Interest-free Loan to Support Final Development Stage of Lead Product, NBTXR3 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that Bpifrance has awarded the Company an interest-free loan of EUR 2M for Innovation (pret a taux zero pour l'Innovation - PTZI). more info >> |
|
Wednesday, September 14, 2016 |
|
Nanobiotix Announces Submission for First Market Approval of Lead Product NBTXR3 in Europe |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has filed for market approval (CE Marking) in Europe for its lead product, a first-in-class radio-enhancer, NBTXR3. more info >> |
|
Thursday, July 7, 2016 |
|
Nanobiotix Reports Successful Results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer |
NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced positive results from a Phase I/II clinical trial of its lead product, NBTXR3, for the treatment of locally advanced cancers of the oral cavity, tongue or oropharynx (head and neck cancer, or H&N) in frail and elderly patients. more info >> |
|
Tuesday, May 31, 2016 |
|
Nanobiotix Establishes Promising Preclinical Proof-of-Concept in Immuno Oncology |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that the Company has established preliminary preclinical proof-of-concept (POC) with the lead product NBTXR3 for its new program in Immuno Oncology (IO). more info >> |
|
Friday, April 29, 2016 |
|
Nanobiotix: 2015 Annual Results |
Nanobiotix (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces its audited consolidated results for the fiscal year ended December 31, 2015. more info >> |
|
Tuesday, January 5, 2016 |
|
Nanobiotix Starts a New Research Program, in Immuno Oncology, with Its Lead Product NBTXR3 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that, in addition to its current advanced clinical development program, the Company has started exploring the use of NBTXR3 for combination in Immuno Oncology. more info >> |
|
Thursday, July 2, 2015 |
|
Nanobiotix starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3 |
Nanobiotix (Euronext: NANO), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has been authorized to begin a new clinical trial in liver cancers for its lead NanoXray product, NBTXR3. more info >> |
|
Wednesday, June 10, 2015 |
|
Nanobiotix Reports Positive Preliminary Results in Head and Neck Cancer Phase I/II Clinical Trial with NBTXR3 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive preliminary safety results for its lead NanoXray product NBTXR3, in its head and neck cancer Phase I/II clinical trial. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
$9.25 Million in Investments Committed to Start-ups during FinTech World Cup at Dubai FinTech Summit
May 14, 2024 13:02: JST
|
|
|
DENSO and Certhon Introduce Artemy, A Fully Automated Cherry Truss Tomato Harvesting Robot
May 14, 2024 11:02 JST
|
|
|
Rover Provides Permitting Update on Let's Go Lithium Project, NV, USA
May 14, 2024 07:00 HKT/SGT
|
|
|
Global News and Publishing Platform Gnomi Launches Paid Journalism Program
May 13, 2024 23:15 HKT/SGT
|
|
|
$9.25 Million in Investments Committed to Start-ups during FinTech World Cup at Dubai FinTech Summit
May 13, 2024 19:58 HKT/SGT
|
|
|
富士通、スーパーコンピュータ「富岳」の世界ランキング結果を発表
May 13, 2024 19:00: JST
|
|
|
Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings
May 13, 2024 18:32 JST
|
|
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures
May 13, 2024 17:06 JST
|
|
|
Datacloud APAC: Charting the Course for APAC's Cloud Future
May 13, 2024 16:00 HKT/SGT
|
|
|
Thailand: Ivy launches plum and tamarind juice drinks in SIG XSlimBloc carton packs
May 13, 2024 15:00 HKT/SGT
|
|
|
3rd Annual Clean Power & New Energy 2024
May 13, 2024 14:03 HKT/SGT
|
|
|
Ogier and TOYOTA GAZOO Racing triumph again
May 13, 2024 14:36 JST
|
|
|
日清食品公布2024年首季度业绩
May 13, 2024 13:00 HKT/SGT
|
|
|
日清食品公布2024年首季度業績
May 13, 2024 12:57 HKT/SGT
|
|
|
Spa points haul for TOYOTA GAZOO Racing
May 13, 2024 13:56 JST
|
|
|
|
More News >> |
|
|
|
|
|